Opinion|Videos|March 18, 2024
Community Partnership: Increasing Public Awareness of CVD
Natalie Evans, MD, MS, FAHA, describes a successful community awareness campaign, which she hopes will serve as a model for future advocacy efforts.
Advertisement
Episodes in this series
Advertisement
Related to this article
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.
At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
3
5 Things to Know About the One Big Beautiful Bill Act
4
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
5